Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
J Affect Disord. 2021 Dec 1;295:225-234. doi: 10.1016/j.jad.2021.08.046. Epub 2021 Aug 26.
Many patients with major depressive disorder (MDD) experience substantial impairment despite the availability of efficacious treatments. We performed a systematic review and meta-analysis to compare antidepressant outcomes in MDD with or without physical or psychiatric comorbidities.
Pubmed, EMBASE, and PsycInfo were searched up to May 14th, 2020 using keywords including MDD, antidepressant, medication, and comorbid. 1915 studies were reviewed. Studies that performed a direct and quantitative comparison of antidepressant effect in patients with MDD with or without comorbidities were included. Study characteristics and primary outcomes were extracted. Continuous and dichotomous variables were considered using standardized mean difference (SMD). Heterogeneity was measured using χ and I tests. Risk of bias was assessed using Cochrane Risk of Bias tool and NIH Quality Assessment Tool.
26 studies met selection criteria. Studies of physical (6 studies; I = 57.69%, p = 0.04) and psychiatric comorbidities (20 studies; I = 75.75%, p < 0.001) were heterogeneous. When compared to patients with MDD without comorbidities, those with physical (SMD = -0.19, 95% CI: -0.30 to -0.08, p = 0.001; 1910 and 2905 patients with or without comorbidities) or psychiatric comorbidities (SMD = -0.20, 95% CI: -0.31 to -0.095, p < 0.001; 4308 and 6867 patients with or without comorbidities) had worse antidepressant outcomes.
Our limitations included aggregating the comorbidities into physical and psychiatric comorbidities and the high heterogeneity of the studies.
Our review provides updated evidence demonstrating that patients with MDD and physical or psychiatric comorbidities experience worse antidepressant outcomes.
尽管有有效的治疗方法,但许多患有重度抑郁症(MDD)的患者仍会经历严重的障碍。我们进行了一项系统评价和荟萃分析,以比较伴有或不伴有躯体或精神共病的 MDD 患者的抗抑郁治疗结果。
使用包括 MDD、抗抑郁药、药物治疗和共病等关键词,检索了 Pubmed、EMBASE 和 PsycInfo,检索时间截至 2020 年 5 月 14 日。共评价了 1915 项研究。纳入了直接比较伴有或不伴有共病的 MDD 患者抗抑郁治疗效果的研究。提取了研究特征和主要结局。使用标准化均数差(SMD)评估连续和二分类变量。使用 χ ²和 I ²检验测量异质性。使用 Cochrane 偏倚风险工具和 NIH 质量评估工具评估偏倚风险。
26 项研究符合选择标准。躯体(6 项研究;I²=57.69%,p=0.04)和精神共病(20 项研究;I²=75.75%,p<0.001)的研究存在异质性。与无共病的 MDD 患者相比,伴有躯体(SMD=-0.19,95%CI:-0.30 至-0.08,p=0.001;有或无共病的患者 1910 例和 2905 例)或精神共病(SMD=-0.20,95%CI:-0.31 至-0.095,p<0.001;有或无共病的患者 4308 例和 6867 例)的患者抗抑郁治疗效果更差。
我们的局限性包括将共病合并为躯体和精神共病,以及研究的高度异质性。
我们的综述提供了更新的证据,表明患有 MDD 且伴有躯体或精神共病的患者抗抑郁治疗效果更差。